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ABSTRACT: Individuals with Down syndrome (DS, tri-
somy 21) exhibit a pro-oxidative cellular environment as
well as mitochondrial dysfunction. Increased oxidative
stress may damage the mitochondrial DNA (mtDNA).
The coexistence of mtDNA variants in a cell or tissue
(i.e., heteroplasmy) may contribute to mitochondrial dys-
function. Given the evidence on mitochondrial dysfunc-
tion and the relatively high incidence of multiorganic
disorders associated with DS, we hypothesized that car-
diac tissue from subjects with DS may exhibit higher fre-
quencies of mtDNA variants in comparison to cardiac
tissue from donors without DS. This study documents
the analysis of mtDNA variants in heart tissue samples
from donors with (n = 12) and without DS (n = 33) us-
ing massively parallel sequencing. Contrary to the original
hypothesis, the study’s findings suggest that the cardiac
mitochondrial genomes from individuals with and without
DS exhibit many similarities in terms of (1) total num-
ber of mtDNA variants per sample, (2) the frequency of
mtDNAvariants, (3) the type of mtDNAvariants, and (4)
the patterns of distribution of mtDNA variants. In both
groups of samples, the mtDNA control region showed sig-
nificantly more heteroplasmic variants in comparison to
the number of variants in protein- and RNA-coding genes
(P < 1.00×10−4, ANOVA).
Hum Mutat 00:1–7, 2016. C© 2016 Wiley Periodicals, Inc.
KEY WORDS: Down syndrome; trisomy 21; hetero-
plasmy; cardiac; mitochondrial variants; massively parallel
sequencing
Introduction
Mitochondria are organelles critical for various cellular func-
tions including the synthesis of ATP by oxidative phosphorylation,
maintenance of cellular calcium homeostasis, and detoxification of
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reactive oxygen species (ROS) generated from cellular respiration
[Nicholls, 2002]. Each mitochondrion contains multiple copies of
mitochondrial DNA (mtDNA), and there are hundreds to thou-
sands of mtDNA copies per cell [Ye et al., 2014]. Human mtDNA
is a double-stranded circle of 16,569 base pairs. The mitochondrial
genome contains a noncoding control region (CR), 13 genes encod-
ing for proteins of the oxidative phosphorylation system, 22 tRNA
genes, and two rRNAs genes. Damage tomtDNA can result inmito-
chondrial dysfunction. Mitochondrial dysfunction contributes to a
number of metabolic and degenerative diseases, and is also involved
in cancer and ageing (Wallace, 2005). Metabolically active tissues
such as heart and brain are especially susceptible to the bioener-
getic deficits resulting from mitochondrial dysfunction (Wallace
and Chalkia, 2013).
Individuals with Down syndrome (DS, trisomy 21) exhibit mi-
tochondrial dysfunction (Arbuzova et al., 2002; Ogawa et al., 2002;
Roat et al., 2007; Infantino et al., 2011; Coskun and Busciglio, 2012).
Mitochondrial dysfunction has been associated with the etiology of
early-onset dementia in patients with DS. Higher frequency of mu-
tations in mtDNA, specifically in the CR, and decreased mtDNA
copy numbers have been observed in brains of patients with DS and
dementia in comparison to age-matched controls (Coskun, et al.,
2010). The exact molecular events linking variation in mtDNA se-
quence to disease are not yet fully characterized (Dai, et al., 2012).
Some individuals with DS display signs and symptoms of prema-
ture ageing in specific body systems including the endocrine, mus-
culoskeletal, immunological, and neurological systems. The cardio-
vascular system seems to be less affected by ageing in the DS setting,
for example, the incidence of hypertension and ischemic cardiac
disease is relatively low in adults with DS (Zigman, 2013). How-
ever, patients with acute leukemia and DS may be more susceptible
to the cardiotoxic effects of anticancer anthracycline drugs (Hefti
and Blanco, 2016). A recent study suggests that in myocardial tissue
from individuals with DS, the expression of certain anthracycline
metabolizing enzymes (i.e., AKR7A2) and mtDNA content are im-
portant variables in determining the cardiac synthesis of toxic drug
metabolites (Hoefer, et al., 2016). Increases in the frequency of spe-
cificmtDNA variants (i.e., heteroplasmy) in cardiac tissuemay con-
tribute to the development of cardiac dysfunction that does occur
in some cases with DS (Balli, et al., 2016; Vetrano, et al., 2016). Re-
cently, we documented a nonsignificant 30%decrease in the levels of
cardiac mtDNA and a nonsignificant 30% increase in the frequency
of the “common” mtDNA4977 deletion in heart tissue samples from
donors with DS (n = 11) in comparison to samples from donors
without DS (n = 31). We noted that the trend toward decreased
mtDNA content in DS hearts seemed to be independent from the
donor’s age (Hefti, et al., 2016). Thus, and given both the evidence
C© 2016 WILEY PERIODICALS, INC.
on mitochondrial dysfunction and the relatively high incidence of
multiorganic disorders associated with DS, we hypothesized that
cardiac tissue from subjects with DS may exhibit higher numbers
and frequencies of mtDNA variants in comparison to cardiac tis-
sue from donors without DS (Hwang and Jea, 2013; Glasson, et al.,
2014; Head, et al., 2015). With the exception of data on mtDNA
heteroplasmy derived from brain tissue from subjects with DS and
a report on tissular heteroplasmy from Naue et al. (2015), there
is a noticeable paucity of reports describing the extent of mtDNA
heteroplasmy in most tissues (Coskun and Busciglio, 2012; Naue,
et al., 2015). This is especially true with regards to cardiac tissue
from subjects with DS.
Massively parallel sequencing is a robust, high-throughput tech-
nique that allows the accurate identification of heteroplasmic
mtDNA variants. This method was pioneered by Tang and Huang
(2010) for identifying mitochondrial heteroplasmy in 2010. The
analysis of mtDNA variants by massively parallel sequencing will
contribute to expand our understanding of the molecular bases un-
derlying mitochondrial dysfunction in various clinical settings, in-
cluding DS. In this study, massively parallel sequencing was applied
to the analysis and annotation of heteroplasmic mtDNA variants in
a collection of heart tissue samples from donors with and without
DS. These data provide the first insights into the extent of hetero-
plasmic mtDNA variation in the cardiac tissue of individuals with
DS.
Materials and Methods
Heart Samples
The Institutional Review Board at the University at Buffalo ap-
proved this research. Heart samples from donors with (n = 12) and
without DS (n = 33) were procured from The National Disease Re-
search Interchange, The Cooperative Human Tissue Network, and
the National Institute of Child Health and Human Development
Brain and Tissue Bank. The postmortem to tissue recovery interval
was 10 hr. Samples (0.50–20 g, myocardium, left ventricle only)
were frozen immediately after recovery and stored in liquid nitro-
gen until further processing. The main demographics from donors
with and without DS are summarized in Suppl. Table S1. DS sta-
tus (yes/no) and relevant diagnoses (when available) were obtained
from anonymous medical histories. Heart samples were processed
following standardized procedures to isolate total cardiac DNA as
described (Hefti, et al., 2016). Age matched groups (n = 10 for each
group) were utilized for some comparisons to minimize the poten-
tial confounding effect of age on mtDNA variation (mean ageNDS
= 46.50 years, SD = 22.40 vs. mean ageDS = 46.6, SD = 21.83, P = 0.99,
Student’s t-test) (Sevini, et al., 2014; Naue, et al., 2015).
Cardiac mtDNA Amplification
The entiremitochondrial genomewas amplified in two fragments
using high-fidelity long-distance PCR (LD-PCR) with Takara LA
(Clontech, CA) as described by Tang and Huang (2010). Cardiac
mtDNA fragment 1 (9,289 bp in length) was amplified with the
following primers: forward 5′-AACCAAACCCCAAAGA CACC-3′,
reverse 5′-GCCAATAATGACGTGAAAGTCC-3′. Cardiac mtDNA
fragment 2 (7,626 bp in length) was amplified with the follow-
ing primers: forward 5′-TCCCACTCCT AAACACATCC-3′, reverse
5′-TTTATGGGGTGATGTGAGCC-3′. The LD-PCR amplification
conditions were as follows: 25 cycles at 94°C for 25 sec and 68°C for
16min. PCR amplification products were analyzed by electrophore-
sis on agarose gels andpurifiedwith suitable kits (BioBasic,Ontario,
CA). DNA concentrations were determined with the PicoGreen
Assay (Invitrogen, Waltham, MA).
Massively Parallel Sequencing
cDNA libraries were prepared with Nextera sample preparation
kits (Illumina, San Diego, CA). The cDNA libraries were quantified
using a PicoGreen assay (Invitrogen) and Kapa qPCR library quan-
tification kit (Kapa Biosystems, Wilmington, MA). Size and quality
of cDNA libraries were confirmed using anAgilent Bioanalyzer 2100
(Santa Clara, California) DNA high-sensitivity chip. The cDNA li-
braries were then pooled based on qPCR values. cDNA products
were sequenced in rapid mode on an Illumina HiSeq 2500 DNA
sequencing system at the University at Buffalo Genomics and Bioin-
formatics Core Facility (Buffalo, NY). The sequencing data were up-
loaded to GenBank (http://www.ncbi.nlm.nih.gov/genbank/). The
accession number for the data is SRP074312.
Sequencing Output Analysis
Paired sequence reads were demultiplexed using Illumina’s
bcl2fastq version 1.8.4. Reads were then mapped to the mitochon-
drial genome NC 012920.1 (version GI: 251831106) utilizing the
CLCGenomicsWorkbench version 8.0.1 alignment tool (Venlo, The
Netherlands). Aftermapping, reads underwent variant calling using
CLCGenomicsWorkbench (v8.0.1) requiring a minimum coverage
of 1,000X and a minimum frequency of 1.00×10–6. An average of
7.50 million reads were mapped for each sample. Imported refer-
ence data from dbSNP was used to identify mitochondrial variants,
which were compiled into Microsoft Excel spreadsheets for further
analysis. Data on mtDNA variants were submitted to the MITO-
MAP database (www.mitomap.org). Diagnostic single-nucleotide
polymorphisms (SNPs) available on the MITOMAP database were
utilized to identify mtDNA haplogroups (Suppl. Table S1). Dis-
tributions and frequencies of heteroplasmic mtDNA variants were
mapped on a circular plot using the Circlize package in R.
Data Analysis
The mean number of heteroplasmic mtDNA variants present in
a locus was obtained from the average number of individual hetero-
plasmic variants present in the specified location from all samples
within the groups being considered. The frequency represents the
percentage of mitochondrial genomes that contain a specific vari-
ant. Mean frequency values present in a locus were obtained from
the average frequency of all heteroplasmic mtDNA variants present
in the specified location from all samples within the group. Fre-
quency values were used to classify mtDNA variants after the ap-
plication of a conservative 2% error rate (He, et al., 2010). mtDNA
variants exhibiting frequency values between 2% and 98% range
were considered heteroplasmic. The D’Agostino and Pearson om-
nibus tests were used to ascertain the normality of datasets. Two-
tailed Student’s t-test was used to compare the means of normally
distributed datasets, and the Mann-Whitney U test was used to
compare the means of non-normally distributed datasets. Correla-
tion analyses were performed with Pearson’s product-moment test.
Analysis of variance (ANOVA) with post-hoc Turkey’s test was used
to compare mean number of variants and mean frequency. In all
cases, differences betweenmeanswere considered to be significant at
P < 0.050.
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Figure 1. A: Heteroplasmic mtDNA variants in cardiac tissue from
donors with and without DS. Rings 1 and 2 show the density of mtDNA
variants in tissue samples from donors with (red, n = 12) and without
DS (black, n = 33). Ring 3 shows the frequency of the corresponding
variants. The closer the circle is to the outer region of ring 3, the higher
the frequency of the variant. Ring 4 indicates the genes or regions of the
mitochondrial genome. B: Map of heteroplasmic mtDNA variant density
and frequency in heart samples from age-matched groups of donors
with and without DS (n = 10 for both groups).
Results
Cardiac mtDNA Variants in Samples from Donors with and
Without DS
Figure 1A shows the distribution and frequency of heteroplasmic
mtDNAvariants in heart samples fromdonorswith (red,n = 12) and
without (black, n = 33) DS. The CR and theMT-ND1 gene showed
relative increases in the density of mtDNA variants in comparisons
to other loci in the mitochondrial genome (Fig. 1A). The frequency
values associated with the heteroplasmic variants in the CR and
the MT-ND1 gene were highly variable and ranged from 2.03% to
95.96% forMT-ND1 and 2.01% to 97.80% for the CR.
There were 415 heteroplasmic mtDNA variants in the group of
heart samples from subjects without DS (12.57 heteroplasmic vari-
ants per sample). According to the NCBI dbSNP database, 89 of
the variants (21.44%) have been previously identified; however,
these variants have not yet been associated to a particular disease
state. Of the remaining mtDNA variants, 323 (77.83%) have not
yet been previously identified, and three (0.72%) were identified
as pathogenic or possibly pathogenic by NCBI dbSNP and MITO-
MAP databases. Specifically, the single-nucleotide variants (SNVs)
rs200145866:T>C (Ile165Thr), rs1599988:T>C (Tyr304His), and
rs28357980:A>G (Asn150Asp) have been associated with the patho-
genesis of Leber’s optic neuropathy (Johns and Berman, 1991;
Yu-Wai-Man and Chinnery, 1993; Howell, et al., 1995). The fre-
quency values of these potentially pathogenic mtDNA variants in
cardiac tissuewere97.25%,95.97%, and96.71%.Therewere73non-
synonymous SNVs in the group of samples from donors without
DS (mean = 2.21, SD = 1.41 nonsynonymous variants per sample).
Figure 1A compiles the distribution and frequency values of
mtDNA variants in 12 cardiac mitochondrial genomes from donors
with DS. The CR of mitochondrial genomes from individuals with
DS showed a relative increase in the density of variants in com-
parison to the other mtDNA regions (Fig. 1A). There was an area
of increased mtDNA variant density in MT-ND1, similar to the
NDS group. In general, heteroplasmic mtDNA variants were more
prevalent in the CR and protein coding regions.
There were 127 mtDNA variants in the group of heart tissue
samples from donors with DS (10.6 variants per sample). Twenty-
nine variants (22.83%) were previously identified and are present
in the NCBI dbSNP database. These variants have not yet been
clinically associated with any disease state. Ninety-eight mtDNA
variants (77.16%) are currently unidentified and are not present in
the NCBI dbSNP database. There were no pathogenic or potentially
pathogenic mtDNA variants in the group of cardiac mitochondrial
genomes from individuals with DS. There were 25 nonsynonymous
heteroplasmic mtDNA variants, with an average of 2.08 (SD = 2.28)
nonsynonymous variants per sample in donors with DS.
Cardiac mtDNA Variants in Samples from Age-Matched
Donors with and Without DS
Aging affects mtDNA heteroplasmy in tissues (Sevini, et al.,
2014; Naue, et al., 2015). Thus, we compared cardiac heteroplas-
mic mtDNA variants in a subset of age-matched samples to control
for this potential confounder. Figure 1B shows the distribution and
frequency of heteroplasmic mtDNA variants in age-matched heart
samples from donors with (red) and without (black) DS. The dis-
tribution of variants and corresponding frequency values across the
mitochondrial genomes from donors with and without DS were
similar (Fig. 1A and B).
Overall, the number of mtDNA variants per gene were similar
between age-matched samples from donors with and without DS
(Suppl. Table S2; Table 1). In age-matched samples from donors
with DS, there was a trend toward a decrease in the mean fre-
quency (freq%) of mtDNA variants in the hypervariable control
region (HCR) versus the regulatory control region (RCR) (mean
freq%DS-HCR = 11.54, SD = 18.62 vs. mean freq%DS-RCR = 30.45,
SD = 7.32, P = 0.070, Mann-Whitney U test). This trend was
not apparent in the group of age-matched samples from donors
without DS (mean freq%Non-DS-HCR = 35.97, SD = 42.94 vs. mean
freq%Non-DS-RCR = 30.33, SD = 7.28, P = 0.54,Mann-Whitney U test).
Samples from donors with and without DS also showed similar
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Table 1. Comparison of Number and Frequency of Heteroplasmic mtDNA Variants in Control Region, Protein Coding Region, and RNA
Coding Region in Heart Samples from Age-Matched Donors with and Without DS (n = 10 Samples for Both Groups)
Down syndrome(mean ± SD) Non-Down syndrome(mean ± SD) P valuea
Control region variants Mean variant number 7.20 ± 3.85 8.60 ± 2.46 0.40
Mean variant frequency (freq%) 31.06 ± 7.23 33.62 ± 10.38 0.54
Protein coding variants Mean variant number 2.30 ± 1.55 3.20 ± 1.40 0.11
Mean variant frequency (freq%) 25.68 ± 30.62 18.61 ± 17.61 0.68
RNA coding variants Mean variant number 0.80 ± 0.92 0.80 ± 0.63 0.77
Mean variant frequency (freq%) 16.17 ± 30.01 16.95 ± 30.91 0.85
aStudent’s t-test used for comparisons of normally distributed data; Mann-Whitney U test used for non-normally distributed data.
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Figure 2. Linear regression analysis of the number of protein cod-
ing variants in mtDNA versus age in heart samples from age-matched
donors with and without DS (n = 10 samples for both groups, non-DS
= 0.57, P = 0.080 vs. rDS = −0.27, P = 0.46, Pearson’s Product-Moment
correlation). Each symbol represents the total number of protein coding
variants per sample.
distributions of mtDNA variants along the binding motifs for es-
sential mitochondrial transcription factors (Suppl. Table S3).
There was a trend toward a positive correlation between the
total number of protein coding mtDNA variants and age in the
group of age-matched samples from donors without DS (r = 0.57,
P = 0.080, Pearson’s Product-Moment correlation). The trend was
not evident in the group of age-matched samples from donors with
DS (r = –0.27, P = 0.46, Pearson’s Product-Moment correlation; Fig.
2). There were no significant correlations between either the num-
ber or frequency of heteroplasmic mtDNA variants and age in both
age-matched groups (Table 2).
There were no significant differences in RNA or protein coding
nonsynonymous, synonymous, or SNV number or frequency be-
tween the age-matched groups (Table 3). There were no statistically
significant differences in the number of RNA or protein coding in-
sertions and deletions (INDELs) between the age-matched groups
(Table 3). The coding INDELs observed in both groups ranged from
1 to 9 bp in length.
The mean number of mtDNA variants in the CR, protein, and
RNA coding regions were significantly different in both groups of
age-matched samples (ANOVANon-DS andANOVADS, P < 1.00×10–4;
Fig. 3). The number of heteroplasmic mtDNA variants located in
RNA coding regions was lower than the number of variants in pro-
tein coding and CR, respectively (Fig. 3). In terms of protein coding
mtDNA variants, both groups of samples showed a preponderance
of nonsynonymous over synonymous variants (non-DS: 84.38%;
DS: 78.26%). The number of nonsynonymous variants per sample
was similar between both groups (Table 3).
Discussion
Massively parallel sequencing allows the examination of tissular
mtDNA variants with a very high depth of coverage (>1,000×).
With the exception of data on mtDNA variants derived from brain
tissue from subjects with DS, there is a noticeable paucity of reports
describing the extent of mtDNA heteroplasmy in most tissues, in-
cluding cardiac tissue, from subjects with DS. This is noteworthy
because several lines of evidence suggest that widespreadmitochon-
drial dysfunction contributes to many of the pathophysiological
alterations associated with DS (Coskun and Busciglio, 2012; Pagano
and Castello, 2012). Despite these pathophysiological alterations,
the current life expectancy for individuals with DS has reached the
sixth decade of life with some individuals (10%) living up to
70 years of age; this increase is attributed to improved medical care
for those with DS (Brown, et al., 2001; Head, et al., 2015). In this
study, massively parallel sequencing was applied to the analysis of
mtDNA heteroplasmy in a collection of heart tissue samples repre-
sentative of the current life span for persons with DS. For compari-
son, mtDNA heteroplasmy was analyzed in a group of samples from
subjects without DS, which included an age-matched subgroup.
Our initial hypothesis postulated that the cardiac mitochondrial
genomes from subjects with andwithoutDSwould showdifferences
in the number and/or distribution of mtDNA variants. However,
the study’s main findings suggest that the cardiac mitochondrial
genomes from individuals with and without DS exhibit many sim-
ilarities in terms of (1) total number of mtDNA variants per sam-
ple, (2) the frequency of mtDNA variants, (3) the type of mtDNA
variants, and (4) the patterns of distribution of mtDNA variants
(Fig. 1; Suppl. Table S2). At first glance, these findings are surprising
given that DS status has been associated with increased intracellular
generation of damaging ROS combined with less effective mtDNA
repair mechanisms (Druzhyna, et al., 1998; Roat, et al., 2007). How-
ever, studies that considerednoncardiac cells (e.g.,DS astrocytes and
lymphocytes) showed that trisomic samples displayed an “adaptive
response” to the chronic increase in oxidative stress. This “adaptive
response” results in an overall decrease inmitochondrial function in
order to minimize the production of ROS and reduce further dam-
age to the mtDNA (Perluigi and Butterfield, 2012; Helguera, et al.,
2013). It is possible that this “adaptive response” is present in the
myocardial tissue of individuals withDS through the entire lifespan.
The result would be the preservation of the cardiac mitochondrial
genome, as manifested by levels of mtDNA variation comparable
to the non-DS setting, at the expense of relative decreases in mi-
tochondrial function. Further comparative studies in cardiac tissue
samples and/or cellular models (e.g., induced pluripotent stem cell
derived cardiomyocytes) would be needed to determine whether the
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Table 2. Correlation Analysis of Heteroplasmic mtDNA Variant Number and Frequency with Age in Age-Matched Donors with and
Without DS (n = 10 Samples for Both Groups)∗
Down syndrome Non-Down syndrome
r P value r P value
Control region variants versus age Mean variant number 0.44 0.20 0.25 0.48
Mean variant frequency (freq%) –0.15 0.68 –0.016 0.96
Protein coding variants versus age Mean variant number –0.27 0.46 0.57 0.080
Mean variant frequency (freq%) 0.10 0.79 0.16 0.66
RNA coding variants versus age Mean variant number 0.32 0.37 0.042 0.48
Mean variant frequency (freq%) –0.77 0.072 0.20 0.70
∗Pearson’s Product-Moment correlation analysis.
Table 3. Comparison of SNVs, Coding INDELs, andNonsynonymous HeteroplasmicmtDNAVariants in Heart Samples fromAge-Matched
Donors with and Without DS (n = 10 Samples for Both Groups)
Down syndrome(mean ± SD) Non-Down syndrome(mean ± SD) P valuea
Single-nucleotide variants (SNVs)b Mean variant number 6.00 ± 2.94 7.60 ± 3.50 0.25
Mean variant frequency (freq%) 24.50 ± 17.90 32.54 ± 21.33 0.32
Coding insertions and deletions (INDELs) Mean variant number 0.70 ± 1.34 1.20 ± 1.03 0.17
Mean variant frequency (freq%) 6.19 ± 15.11 15.74 ± 21.56 0.12
Nonsynonymous SNVs Mean variant number 1.30 ± 1.25 2.10 ± 1.37 0.18
Mean variant frequency (freq%) 8.37 ± 11.74 12.92 ± 15.44 0.40
aStudent’s t-test used for comparisons of normally distributed data; Mann-Whitney U test used for non-normally distributed data.
bTotal SNV in coding and noncoding regions.
Figure 3. Mean number of heteroplasmic mtDNA variants (protein
coding, RNA coding, and control regions) in heart samples from age-
matched donors with and without DS (n = 10 samples for both groups).
Each bar represents the mean ± SD. ∗P < 0.050 (one-way ANOVA with
post-hoc Turkey test).
control of cardiac mtDNA heteroplasmy in the trisomic setting is
associated with compensatory changes in mitochondrial function.
This study documented relatively high numbers of mtDNA vari-
ants in cardiac tissue (Tables 1 and 2). Cardiac tissue is mostly
composed of postmitotic cells, and the majority of the cardiomy-
ocytes in an individual will not be replaced during a normal lifespan
(Bergmann, et al., 2009). Thus, the low turnover of cardiac tissue
may result in the accumulation and propagation of certain het-
eroplasmic mtDNA variants (Taylor and Turnbull, 2005; Tuppen,
et al., 2010). Heart tissue samples from donors with and without
DS showed a wide range of heteroplasmy (i.e., >2%–<98%), and
mtDNA variants with frequency values near the upper limit may be
in fact homoplasmic mtDNA variants. In general, there was good
agreement between the donor’s ethnicity as listed in the available
clinical reports (i.e., “white” or European American and “black” or
African American) and corresponding mtDNA haplogroups from
Africa and Europe (Suppl. Table S1). However, in the absence of
paired samples of maternal DNA, it was not possible to: (1) estimate
the fraction of haplotype associated variants, and (2) estimate the
fractions of germline and “de novo” mtDNA variants (He, et al.,
2010).
In both groups of samples, the variants with the highest degree
of heteroplasmy tended to concentrate in the CR and theMT-ND1
gene. The CR is critical for transcription and regulation of the mi-
tochondrial genome. The CR is the most variable region in the
mitochondrial genome. Naue et al. (2015) examined mtDNA vari-
ants in the CR in nine different tissues from 100 individuals, and
found similar numbers of mitochondrial point heteroplasmies in
heart and brain, whereas skeletal muscle and liver exhibited the
highest number of heteroplasmies. Variation in the CR may af-
fect mtDNA copy number (i.e., mtDNA content) (Coskun, et al.,
2010). In a previous study involving this set of heart samples, we
documented a nonsignificant 30% (P = 0.65) decrease in mtDNA
content in samples with DS in comparison to samples without DS
(Hefti, et al., 2016). Coskun et al. (2010) examined the frequency
of mtDNA CR mutations in samples from cerebral frontal cortices
from age-matched subjects with and without DS, and found that
mean mutation frequencies were similar between both groups. In
agreement, heart tissue samples from subjects with and without
DS showed similar levels of heteroplasmy when considering the en-
tire CR as well as distinct regulatory elements within the CR that
are involved in the replication of mtDNA (Fig. 1A and B; Suppl.
Table S3).
Age-matched groups of cardiac samples from donors with and
without DS displayed similar distribution and mean frequency val-
ues of heteroplasmic mtDNA variants in RNA and protein coding
genes (Fig. 1B). Both groups displayed reduced numbers of RNA
variants, as well as reduced numbers of protein coding variants
in comparison to the number of variants in the CR (Fig. 3). The
majority of the protein coding variants in both groups were non-
synonymous, therefore, potentially damaging. In general, increased
numbers and frequencies of mtDNA variants in protein coding and
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tRNA coding regions are more likely to be pathogenic compared
with other mtDNA regions (Ye, et al., 2014). This pattern of re-
gional variation in cardiac mtDNA is consistent with the recent
conclusions made by Ye et al. (2014) after analyzing massively par-
allel sequencing data from the 1000 Genomes Project. The authors
proposed that a purifying selection process may reduce the preva-
lence and accumulation of potentially pathogenic mtDNA variants
in specific mitochondrial loci such as tRNAs and protein coding
genes to avoid the propagation of mitochondrial dysfunction (Ye,
et al., 2014).
There are limitations in the present study. The sample size was
limited due to the scarcity of good quality cardiac tissue samples
from donors with DS; this common problem impacts research
on many of the issues concerning the pathobiology of DS (Oster-
Granite, et al., 2011). Thus, it was not possible to detect relatively
subtle differences inmtDNA frequencies (Suppl. Table S4). The lack
ofmatchedmaternal tissue samples precluded determining whether
the cardiac mtDNA variants were either inherited or acquired (i.e.,
somatic)mtDNAvariants. Thus, the observed frequency valuesmay
not fully reflect the impact of DS status on somatic mtDNA vari-
ants. Furthermore, the reliance on cadaveric tissue samples from
donors with various clinical histories makes it almost impossible
to control for potential clinical confounders. Furthermore, the re-
sulting cross-sectional nature of the comparisons should be con-
sidered when evaluating the potential impact of age and/or other
putative covariables on heteroplasmic mtDNA frequencies (Sevini,
et al., 2014). Although massively parallel sequencing is a powerful
method for the analysis of mtDNA variants in human tissues, it
often cannot detect large deletions in mtDNA. For example, the
“common”mtDNA 4,977 bp deletion cannot be reliably detected by
massively parallel sequencing because of its relatively low frequency
in cardiac tissue (DS% frequency mtDNA4977deletion: 0.0086 ± 0.0166, non-
DS% frequency mtDNA4977deletion: 0.0066 ± 0.0124; P = 0.514) (Tang and
Huang, 2010; Hefti, et al., 2016).
The results from this study suggest similar distribution of het-
eroplasmic mtDNA variants in hearts from individuals with and
without DS. The data presented in this study offer a glimpse into
the patterns of heteroplasmicmtDNAvariants in cardiac tissue from
donors with DS. These data may advance our understanding of tis-
sular mtDNA variation and its potential relation to the complex
pathobiology of DS.
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